Arthritis: Skin & Rheumatic and Musculoskeletal Diseases

PAR-16-381, RFA-AR-17-008, PAR-16-382, RFA-AR-17-009
X02, R61/R33

The NIAMS Research Innovation for Scientific Knowledge (RISK) initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice.  The RISK program is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms.  The RISK program intends to support disease-focused translational studies, up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.

The RISK program will support the two main scientific areas – Skin & Rheumatic Disease and Musculoskeletal Diseases – of NIAMS mission with separate budgets and time lines.

About the Funding Mechanism:

The X02 is the recommended (not required) first step in the application process for this FOA. Potential applicants should read both FOAs. Investigators whose X02 pre-applications are evaluated to be highly innovative and most relevant to the RISK program, will be notified of the opportunity to submit an R61/R33 application to this FOA.


Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.